Clinical trial

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

NCT07743190

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Paclitaxcel Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumab View linked drug · Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE2

Conditions

Triple Negative Breast Cancer (TNBC)unresolved

Elevated Tumor-Infiltrating Lymphocytesunresolved

Interventions

CarboplatinDRUG · verified · RxNorm: carboplatin

PaclitaxcelDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Medical University of South Carolinalead sponsor

State University of New York - Upstate Medical Universitycollaborator

Mapped research locations

CharlestonSouth Carolina, United States1 SyracuseNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07743190 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.